Cargando…

Ethical Questions Linked to Rare Diseases and Orphan Drugs – A Systematic Review

BACKGROUND: Rare or orphan diseases have become an important target of healthcare activities all over the world. The study aims to identify ethical questions linked to rare diseases and orphan drugs and ethical principles or approaches applied to solve them. METHODS: Relevant peer-reviewed articles...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kacetl, Jaroslav, Marešová, Petra, Maskuriy, Raihan, Selamat, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568613/ https://www.ncbi.nlm.nih.gov/pubmed/33116992 http://dx.doi.org/10.2147/RMHP.S260641

Ejemplares similares

Legislative and ethical aspects of introducing new technologies in medical care for senior citizens in developed countries
por: Kacetl, Jaroslav, et al.
Publicado: (2016)

Challenges and opportunity in mobility among older adults – key determinant identification
por: Maresova, Petra, et al.
Publicado: (2023)

Ethical issues of the use of AI-driven mobile apps for education
por: Klimova, Blanka, et al.
Publicado: (2023)

Medical Device Development Process, and Associated Risks and Legislative Aspects-Systematic Review
por: Marešová, Petra, et al.
Publicado: (2020)

Criteria to define rare diseases and orphan drugs: a systematic review protocol
por: Abozaid, Ghada Mohammed, et al.
Publicado: (2022)

The portal for rare diseases and orphan drugs
por: Singh, Jatinder
Publicado: (2013)

The potential of medical device industry in technological and economical context
por: Maresova, Petra, et al.
Publicado: (2015)

Rare diseases and orphan drugs: Latvian story
por: Logviss, Konstantins, et al.
Publicado: (2014)

Pricing of orphan drugs in oncology and rare diseases
por: Nuijten, Mark, et al.
Publicado: (2020)

The availability and affordability of orphan drugs for rare diseases in China
por: Gong, Shiwei, et al.
Publicado: (2016)

Rare diseases and orphan drugs: 500 years ago
por: Dooms, Marc M.
Publicado: (2015)

Rare Diseases and Orphan Drugs Accessibility in Bosnia and Herzegovina
por: Guzvic, Vladmiri, et al.
Publicado: (2018)

The impact of the rare disease and Orphan Drug Act in Taiwan
por: Hsiang, Ning-Chun, et al.
Publicado: (2021)

Breast Cancer Detection Using Infrared Thermal Imaging and a Deep Learning Model
por: Mambou, Sebastien Jean, et al.
Publicado: (2018)

Rare pulmonary disease and orphan drugs: a path to the future
por: Harari, Sergio, et al.
Publicado: (2019)

Rare disease patients in India are rarely involved in international orphan drug trials
por: Chakraborty, Monoswi, et al.
Publicado: (2022)

A systematic review of moral reasons on orphan drug reimbursement
por: Zimmermann, Bettina M., et al.
Publicado: (2021)

A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act
por: Fermaglich, Lewis J., et al.
Publicado: (2023)

Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019)

Addressing the needs of Canadians with rare diseases: an evaluation of orphan drug incentives
por: Harris, Emily
Publicado: (2018)

Rare diseases: Canada’s “research orphans”
por: Gupta, Samir
Publicado: (2012)

Will Gene Editing Orphanize Rare Diseases?
por: Mann, Douglas L.
Publicado: (2023)

The Ethics of the Sewage Question
Publicado: (1886)

A Question of Ethics
Publicado: (1881)

Smart and Climate-Smart Agricultural Trends as Core Aspects of Smart Village Functions
por: Adesipo, Adegbite, et al.
Publicado: (2020)

A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries
por: Czech, Marcin, et al.
Publicado: (2020)

Novel orphan medicines and abandoned pathways - the US Orphan Drug Act of 1983 and the impact on rare rheumatologic diseases and lysosomal storage disorders
por: Ries, Markus, et al.
Publicado: (2015)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019)

Educational aspects of rare and orphan lung diseases
por: Alfaro, Tiago M., et al.
Publicado: (2021)

Genetic Testing for Rare Diseases: A Systematic Review of Ethical Aspects
por: Kruse, Judith, et al.
Publicado: (2022)

Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?
por: Rodriguez-Monguio, R., et al.
Publicado: (2017)

Orphan Drugs in Neurology—A Narrative Review
por: Sirbu, Carmen Adella, et al.
Publicado: (2023)

Phosphine Toxicity: Ethical Questions
por: Anderson, Elizabeth L.
Publicado: (2006)

A Question of Medical Ethics
por: Cornwall, J. W.
Publicado: (1903)

Vexed Questions in Medical Ethics
Publicado: (1858)

Systematic review of available evidence on 11 high-priced inpatient orphan drugs
por: Kanters, Tim A, et al.
Publicado: (2013)

The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
por: Schuller, Y., et al.
Publicado: (2015)

Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study
por: Gorini, Francesca, et al.
Publicado: (2022)

Financing of Rare Diseases and Orphan Drugs in A Sanctioned Country: A Qualitative Study
por: Naghdi, Seyran, et al.
Publicado: (2022)

To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases
por: Lanar, Sally, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ougikhgm4r3eusseer0r0ng6tk